GGrantIndex
Sort

10,766 grants matching checkpoint inhibitor

Molecular Targeted Radionuclide Therapy to Enhance Tumor Cell Susceptibility and Response to Immune Checkpoint Inhibition

$361,468
Zachary Scott Morris · University Of Wisconsin-Madison · P01 · FY2024 · CA

Project 2: Cytoplasmic chromatin fragments (CCF) as a driver of liver cancer and target for intervention during aging

$361,442
Peter D. Adams · Sanford Burnham Prebys Medical Discovery Institute · P01 · FY2025 · AG

Project 3: Chronic interferon and bile acid signaling as drivers of immunosuppression in age-related liver cancer

$361,441
Susan M Kaech · Sanford Burnham Prebys Medical Discovery Institute · P01 · FY2025 · AG

Project 4: Interrogating and harnessing age-related IFN signaling and innate immunity in HCC prevention and therapy

$361,440
Gen-Sheng Feng · Sanford Burnham Prebys Medical Discovery Institute · P01 · FY2025 · AG

New Strategies for Treatment of NRAS Mutant Melanoma after Progression on Immune Checkpoint Inhibitors

$361,357
Ann Richmond · Vanderbilt University · R01 · FY2024 · CA

Study of Anti-Survival signals in NF1

$361,050
Changyan Chen · Beth Israel Deaconess Medical Center · R01 · FY2012 · CA

Regulation of PD-L1/PD-1 immune checkpoints by cis-interactions

$361,044
Enfu Hui · University Of California, San Diego · R37 · FY2021 · CA

Mucosal Immune Defense Mechanisms of the Urinary Bladder

$361,000
Marco Colonna · Washington University · U01 · FY2011 · AI

Inactivation of Hdac3 in the cause, prevention, and treatment of HCC

$360,974
Scott Hiebert · Vanderbilt University · R01 · FY2014 · CA

Regulation of antigen presenting cells in the tumor microenvironment by retinoic acid

$360,922
Malay Haldar · University Of Pennsylvania · R37 · FY2023 · CA

Lynch Vaccine

$360,907
Steven Monroe Lipkin · Weill Medical Coll Of Cornell Univ · U54 · FY2023 · CA

Immunotherapeutic Modalities for K-ras Mutant Lung Cancer: Sex- and Cell Type-Specific Roles of IL-6/STAT3 signaling

$360,787
Seyed Javad Mirhassani Moghaddam · University Of Tx Md Anderson Can Ctr · R01 · FY2019 · CA

Generating rapid antitumor immunity with lymphocyte-reprogramming nanocarriers

$360,766
Matthias Stephan · Fred Hutchinson Cancer Research Center · R01 · FY2019 · CA

Generating rapid antitumor immunity with lymphocyte-reprogramming nanocarriers

$360,766
Matthias Stephan · Fred Hutchinson Cancer Research Center · R01 · FY2020 · CA

(PQ8) Predicting immune-related toxicity in the adjuvant melanoma setting with checkpoint inhibition

$360,682
Iman Osman · New York University School Of Medicine · R01 · FY2022 · CA

MECHANISMS OF RADIORESISTANCE AND CELL CYCLE PROGRESSION

$360,669
Columbia University Health Sciences · R01 · FY2002 · GM

Epigenetically Engineered Mouse Model for Lung Cancer Therapy

$360,667
Lanlan Shen · Baylor College Of Medicine · R01 · FY2025 · CA

Reprogramming the tumormicroenvironment to improve immunotherapy of glioblastoma

$360,653
Rakesh K. Jain · Massachusetts General Hospital · R01 · FY2024 · CA

Delineating how nucleic acid sensing in tumorcells regulate anti-tumor immune responses

$360,545
Malay Haldar · University Of Pennsylvania · P01 · FY2024 · CA

Metabolic interactions between tumor cells and the immunce system in GBM A potential Achilles heel of GBM for novel therapeutics

$360,522
Loic Pierre Deleyrolle · University Of Florida · R01 · FY2024 · NS

Protein Kinase Signaling and Cell Cycle Control

$360,504
Michael B Yaffe · Massachusetts Institute Of Technology · R01 · FY2007 · ES

Mechanistic basis and therapeutic strategies for ARID1A mutation in ovarian cancer

$360,406
Rugang Zhang · University Of Tx Md Anderson Can Ctr · R01 · FY2024 · CA

Antitumor-Antibiotics from Marine Microorganisms

$360,308
William Fenical · University Of California, San Diego · R37 · FY2008 · CA

Antitumor-Antibiotics from Marine Microorganisms

$360,308
William Fenical · University Of California, San Diego · R37 · FY2007 · CA

Regulatory Dendritic Cells in Cancer

$360,297
Jose R Conejo-Garcia · H. Lee Moffitt Cancer Ctr & Res Inst · R01 · FY2022 · CA